Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT03149120
Phase
PHASE2
Status
Withdrawn

Conditions

  • Soft Tissue Sarcomas

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — BIOLOGICAL
    Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
  • Pazopanib — DRUG
    Pazopanib given at a dose of 800 mg by mouth daily.

Study Details

This trial will assess whether nivolumab alone or nivolumab combined with pazopanib will be associated with an improvement in progression free survival (PFS) at 6 months

Key Dates

Start date
Aug 31, 2017
Status verified
Aug 2017
Primary completion
Aug 17, 2017
Completion
Jun 30, 2022

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab
    Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
  • Experimental: Nivolumab with Pazopanib
    Pazopanib at a dose of 800mg by mouth daily.

Primary Outcome Measure

Progression-free survival (PFS) at 6 months for nivolumab alone or nivolumab in combination with pazopanib [ Time Frame: 6 Months ]

Locations (1)

FacilityCityStateZIPSite coordinators
New York University School of MedicineNew YorkNew York10016-

Find similar trials in New York, NY

By research site
New York University School of Medicine· New York, NY

Related Studies